Company Overview and News

 
Market Live: Nifty tests 10,700, Sensex dips 100 pts amid higher oil prices; rupee trims gains

2018-05-17 moneycontrol
Earnings: Farm equipment maker Escorts has reported stellar earnings growth for the March quarter as it has been firing on all cylinders.

 
Market Live: Sensex falls 100 pts as Brent crude inches up towards $80/bbl

2018-05-17 moneycontrol
Market Update: The market is reeling under pressure with the Sensex falling 100 points as investors after digesting Karnataka election outcome started monitoring earnings, and movement in rupee and crude oil prices.

 
Market Live: Sensex, Nifty mildly lower; RIL, HDFC, Infosys, metals stocks drag

2018-05-17 moneycontrol
Crude Update: Oil prices firmed, with Brent crude creeping ever closer to USD 80 per barrel, a level it has not seen since November 2014, as supplies tighten while demand remains strong.

 
Market Live: Sensex, Nifty off opening highs; all sectoral indices in the green barring metals

2018-05-17 moneycontrol
Buzzing: Tata Steel saw profit booking after opening higher as it reported a consolidated net profit of Rs 14,688 crore for the March quarter, as against a loss of Rs 1,168 crore in the same quarter last year, benefiting from a one-time gain of Rs 11,376.14 crore from the restructuring of its UK business' pension scheme.

 
Century Plyboards (₹280.6): Sell

2018-05-16 premium.thehindubusinessline
The stock of Century Plyboards (India) plummeted 8 per cent with an above average volume on Wednesday, breaking below a key support level of ₹300. This decline provides an opportunity for short-term traders to sell the stock at current levels. After a medium-term uptrend, the stock encountered a key resistance at around ₹360 in January this year. This resistance level capped the stock’s rally in April.

 
Closing Bell: Sensex dips 156 pts, Nifty ends below 10,800; RIL, ICICI, HDFC twin drag

2018-05-16 moneycontrol
Market Closing: Benchmark indices closed sharply lower on Wednesday as uncertainty remained over the formation of government in Karnataka.

 
Market Live: Sensex dips 100 pts; FMCG index jumps on HUL, ITC support

2018-05-16 moneycontrol
Century Plyboards Q4 results: The company has reported 35 percent decline in its Q4 net profit at Rs 36 crore, while revenue was up 11.4 percent at Rs 544.1 crore.

 
Century Plyboards (India) Limited - Dividend

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Century Plyboards (India) Limited - Financial Result Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Market Live: Sensex, Nifty off day#39;s lows amid rupee recovery, fall in oil prices

2018-05-16 moneycontrol
Crude Oil Update: Oil prices fell, weighed down by ample supplies despite ongoing output cuts by producer cartel OPEC and looming US sanctions against major crude exporter Iran.

 
Market Live: Nifty extends losses, Sensex falls over 250 pts; Bank index dips 1%

2018-05-16 moneycontrol
RBI Intervention: The Reserve Bank of India (RBI) likely intervened heavily in the foreign exchange market right from the start of trade on Wednesday to stem any fall in the rupee, three dealers said.

 
Market Live: Nifty extends losses, Sensex falls over 200 pts; Bank index dips 1%

2018-05-16 moneycontrol
Market Update: The market extended losses, with the Sensex falling more than 250 points on correction in banks stocks after disappointing earnings by PNB.

 
Century Plyboards (India) Limited - Trading Window

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Century Plyboards (India) Limited - Option to submit Standalone/Consolidated Financial Results

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

21h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...